Company Overview
Snapshot
Founded in March 2009 by Harvey Kasdan, Accellix operates with 51–200 employees. The company has raised $18.73M across 7 funding rounds from 3 investors. In June 2020, Accellix secured Series D funding.
Business overview
Accellix develops a platform for cell therapy quality control, providing quick and accurate flow cytometry results. Its technology is designed for use on manufacturing floors and at the point of care, enabling partners in cell therapy to meet critical quality control requirements. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Diagnostics Devices, serving healthcare providers and laboratories.
Strategic signal
In May 2021, Accellix expanded its leadership team, signaling a strategic move to strengthen its organizational structure and potentially accelerate growth initiatives. This development suggests the company is preparing for increased operational demands or market expansion, which is a positive indicator for investors looking for scaling opportunities in the cell therapy quality control space.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant leadership development at Accellix?
- In May 2021, Accellix expanded its leadership team, indicating a strategic move to bolster its management capabilities.
- When did Accellix announce its next-generation instrument?
- In April 2020, Accellix announced its next-generation Accellix Instrument and Consumable, designed to further simplify and automate the QC workflow in cell therapy manufacturing.
- What was a key leadership appointment at Accellix?
- In January 2020, Accellix appointed Nir Nimrodi as Chairman.
- Did Accellix engage in any co-development agreements?
- In October 2019, Accellix entered into a co-development agreement with Orgenesis Inc. to integrate Accellix's proprietary optic system, cartridges, reagents, and software into Orgenesis' Point of Care cellular therapy processing services and platform.
- When did Accellix form a joint venture?
- In December 2018, Accellix and Emosis announced their intent to form a joint venture called EmoCellix, focused on marketing a complete solution for hemostasis cytomolecular diagnostics.